

- Attorney Docket No.: O-2002.713 US

IN THE CLAIMS:

1. (Canceled).

2. (Canceled).

3. (Canceled)

4. (Canceled).

5. (Canceled).

6. (Canceled).

7. (Currently Amended) A method of treatment of estrogen-deficiency related complaints in female patients that exhibit these complaints while ~~they~~ the female patients are on treatment with a drug which prevents the synthesis of endogenous estrogen, ~~wherein the treatment comprises the administration to~~ comprising:
administering to said female patients of an effective amount
of tibolone.

8. (Currently Amended) The method of claim 7, wherein the estrogen-deficiency related complaints ~~comprise~~ are climacteric complaints.

Attorney Docket No.: O-2002.713 US

9. (Currently Amended) The method of claim 7 ~~or 8~~, wherein the estrogen-deficiency related complaints ~~comprise~~ are bone loss.

10. (Currently Amended) The method of ~~any one of claims 7-9~~ claim 7, wherein the drug which prevents the synthesis of endogenous estrogen is an aromatase inhibitor. ~~The method of any one of the claims 7-10, wherein the aromatase inhibitor is selected from the group consisting of aminogluethimide, anastrozole, letrozole, exemestane, and formestane.~~

12. (Currently Amended) The method of ~~any one of the claims 7-11~~ claim 7, wherein tibolone is administered in a daily dosage of 0.4 to 2.5 mg.

13. (New) The method of claim 7, wherein the aromatase inhibitor is selected from the group consisting of aminogluethimide, anastrozole, letrozole, exemestane, and formestane.